Navigation Links
Ambit Biosciences To Announce Second Quarter 2014 Financial Results
Date:7/29/2014

SAN DIEGO, July 29, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report second quarter operational results after closing of the NASDAQ Global Market on Tuesday, August 12, 2014.

A conference call hosted by Michael Martino, president and CEO, and other members of senior management will take place on the same day at 5:00 pm EDT (2:00 pm PDT) and will be webcast live on the Ambit website. 

To access the live teleconference call, dial 866-436-9172 in the U.S. and 630-691-2760 for international callers.  Please specify to the operator that you would like to join the "Ambit Second Quarter 2014 Earnings Conference Call," referencing conference ID number 37609634. If you are unable to listen to the live webcast, a teleconference replay will be available through Tuesday, August 19, 2014.  Interested parties can access the replay by dialing 888-843-7419 and entering the passcode 37609634.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Tuesday, September 9, 2014. 

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is cu
'/>"/>

SOURCE Ambit Biosciences
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
2. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
3. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
4. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
5. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
6. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
7. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
8. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
9. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
10. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
11. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... Inc. (Nasdaq: QCOR ) has completed a ... as its independent, registered public accounting firm for the ... BDO to replace Odenberg Ullakko Muranishi & Co. LLP ... "As we continue our strategy to grow through ...
... 4, 2011 Doctors at Beaumont Hospital, Troy ... to correct atrial fibrillation, a prevalent and growing ... is an alternative to open-heart surgery. It,s performed ... a shorter hospital stay. Phillip Robinson, ...
Cached Medicine Technology:Questcor Pharmaceuticals Selects BDO USA as its Auditor 2Beaumont First in State to Perform Robotic Heart Procedure for Atrial Fibrillation 2Beaumont First in State to Perform Robotic Heart Procedure for Atrial Fibrillation 3
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
(Date:1/22/2015)... 2015 Recently, Weddingshe.com has added many trendy ... announced its highest annual revenues in the past three years. ... glamorous wedding dresses. , According to the sales manager of ... promotions for them in 2015. This point can be reflected ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
(Date:1/22/2015)... 22, 2015 JJsHouse.com is a famous dress ... the business announces its latest collection of wedding dresses ... most important issue is the wedding dress on your big ... a woman’s life. Every bride wants to find the most ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Study,s conclusion of no causal link disputes its own ... conflicts of interest, NIXA, Mo., Sept. 26 ... of only 1047 participants, low,compliance rate, and very little ... any reputable journal -- appears to misinform,the public. They ...
... when LDL levels were low, study finds , , WEDNESDAY, ... HDL cholesterol protect against heart disease and stroke no ... are, a new study shows. , The incidence of ... percent lower in the one-fifth of participants in a ...
... (Nasdaq: AMCS ),a leader in radiology and medical image and ... investors at the William Blair & Company Small Cap Growth Stock,Conference ... ), WHEN: ... -- Presentation begins promptly at 11:20 a.m. (Eastern Time), ...
... Ramps ... Million, CHICAGO, Sept. 26 Since its launch in April, more ... and have lost more than three-quarters of a million pounds.,Challenge founder Dr. ... will lead the way to a million pounds lost by the,final stop ...
... Improvement Organization is part of national effort to ... improve health of Medicare ... (QIOs) across the country are working in partnership with,Medicare ... plans,(MA-PDs) to improve the quality of prescription drug therapy ...
... Cancer Awareness in New Hampshire and Seek ... MANCHESTER, N.H., Sept. 26 Susan G. Komen,for ... public policy campaign aimed at,educating and mobilizing New ... make breast cancer a priority -- in their,platforms, ...
Cached Medicine News:Health News:CDC Study Links Thimerosal in Vaccines to Motor/Phonic Tics and Deficits in Attention, Behavior Control, Verbal IQ 2Health News:High HDL Levels Protect Heart Health 2Health News:AMICAS to Present at William Blair & Company Small Cap Growth Stock Conference 2Health News:The Challenge: Make It A Million (Pounds Lost That Is) 2Health News:The Challenge: Make It A Million (Pounds Lost That Is) 3Health News:Delmarva Foundation Implements Medication Therapy Management Program in Maryland and DC 2Health News:Komen for the Cure Launches 'Presidential' Campaign 2
... temperature set by means of a ... button. A green LED indicates the ... amber LED indicates the unit has ... LED and an audible alarm indicates ...
Provides outstanding patient warming and safety throughout the hospital and is nearly half the size and one-third the weight of earlier units....
The QuickVue Advance® G. vaginalis test is an enzyme activity test for use in the detection of Gardnerella vaginalis Proline IminoPeptidase(PIP) activity in vaginal fluid specimens from women su...
The Affirm™ VPIII tests RNA probe technology offers a dependable, rapid means toward early identification and treatment of patients suffering from these pathogens....
Medicine Products: